AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33131308
Drug: Low-intensity shockwave
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity shockwave therapy
Trial: 36207389
Drug: Neostigmine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine administration after tracheal intubation (Group N)
Trial: 36207389
Drug: Neostigmine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine administration (Group N)
Trial: 33775312
Drug: Metformin XR
RxNorm normalized name: metformin Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin XR (500 mg daily increased to 1500 mg)
Trial: 36377973
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of covalent BTK inhibitor
Trial: 33709661
Drug: Electroacupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture combined with conventional Western medicine
Trial: 33302114
Drug: PD-1 inhibitors
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitors
Trial: 32618251
Drug: MDA (Mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDA (Mass Drug Administration)
Trial: 36465342
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CCRT)
Trial: 33930124
Drug: Vaginal micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal micronized progesterone 400 mg twice daily plus oral dydrogesterone 10 mg twice daily
Trial: 32676977
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral administration)
Trial: 34916722
Drug: Same-day PEG-ASC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day PEG-ASC regimen (5 mL sodium picosulfate in the evening and 1.5 L PEG-ASC on the day of colonoscopy)
Trial: 34916722
Drug: Split-dose PEG-ASC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose PEG-ASC regimen (1 L PEG-ASC before the day of colonoscopy and 1 L PEG-ASC on the day of colonoscopy)
Trial: 34916722
Drug: Split-dose PEG-ASC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose PEG-ASC regimen
Trial: 33469832
Drug: Vibegron 75
RxNorm normalized name: vibegron 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibegron 75 mg once daily
Trial: 32090517
Drug: Liraglutide 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 3.0 mg plus IBT
Trial: 32645164
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (Pitavastatin)
Trial: 33341937
Drug: Glyburide treatment
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide treatment in intermediate group
Trial: 33341937
Drug: Glyburide treatment
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide treatment in wild-type genotype group
Trial: 33341937
Drug: Glyburide dosage
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide dosage in variant genotype group
Trial: 33341937
Drug: Glyburide dosage
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide dosage in wild-type genotype group
Trial: 33341937
Drug: Glyburide dosage
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide dosage in intermediate group
Trial: 32893098
Drug: Neurodynamics therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodynamics therapy
Trial: 34039457
Drug: Complete level
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete level C (CC) - passive APR with an anti‐chemical suit
Trial: 33239413
Drug: Topical PHMB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical PHMB 0.06%
Trial: 36177673
Drug: Low-intensity extracorporeal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity extracorporeal shock wave therapy (LiESWT) at 0.25 mJ/mm2 and 3 pulses/second for a total of 3000 pulses over 8 weeks
Trial: 36177673
Drug: Low-intensity extracorporeal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity extracorporeal shock wave therapy (LiESWT)
Trial: 35074890
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (cilostazol with aspirin or clopidogrel) in the 15-28 days group
Trial: 35074890
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (cilostazol with aspirin or clopidogrel) in the 29-180 days group
Trial: 35074890
Drug: Monotherapy (aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (aspirin or clopidogrel) in the 8-14 days group
Trial: 34580947
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of maternal risk factors, mean arterial pressure (MAP), serum placental growth factor (PlGF), and serum soluble fms-like tyrosine kinase-1 (sFLT-1) (triple test)
Trial: 34980184
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine (0.75 mg/kg, max 75 mg)
Trial: 39146562
Drug: Placebo lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lotion
Trial: 34139047
Drug: MM -
RxNorm normalized name: CKMM - Creatine kinase MM isoenzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MM - mechanical debridement + metronidazole-minocycline ointment
Trial: 34353650
Drug: Midazolam and
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam and Haloperidol (5 mg midazolam and 5 mg haloperidol intramuscular injection)
Trial: 32158186
Drug: Apatinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib (500 mg on a 4-week cycle)
Trial: 36163892
Drug: Ibrutinib 420
RxNorm normalized name: ibrutinib 420 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 420 mg once-daily
Trial: 36247079
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9% solution for nasopharyngeal wash
Trial: 34152880
Drug: Topical Lawsonia
RxNorm normalized name: Lawsonia inermis flowering top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Lawsonia inermis L. (Henna) hydrogel (H.gel) applied four times a day for 2 weeks
Trial: 34966120
Drug: Neuromuscular Electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular Electrical Stimulation (NMES) treatment, 4 sessions over 2 weeks
Trial: 35940873
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Low dose and Conventional dose)
Trial: 34351205
Drug: Concurrent expert
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent expert testimony
Trial: 32443036
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme replacement therapy (PERT) with 2000 U lipase/kg/day in 4 doses plus hypercaloric enteral supplements
Trial: 32443036
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received hypercaloric enteral supplements only
Trial: 32251360
Drug: L-dopa/benserazide 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa/benserazide 100/25 mg
Trial: 32319233
Drug: 6 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of platinum-based chemotherapy and niraparib maintenance alone
Trial: 32147084
Drug: Eurhythmy Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eurhythmy Therapy (EYT)
Trial: 32989920
Drug: Filgotinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgotinib (200 mg once daily for 15 days)
Trial: 33462851
Drug: Thompson sampling
RxNorm normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thompson sampling for treatment allocation
Trial: 32612355
Drug: Protein Supplement
RxNorm normalized name: PROTEIN SUPPLEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein Supplement
Trial: 32612355
Drug: WB‐EMS &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WB‐EMS & Protein Supplement
Trial: 36029208
Drug: Dexamethasone therapy
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone therapy for 19 days
Trial: 32960329
Drug: DSM-TACE (drug-eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSM-TACE (drug-eluting beads transarterial chemoembolization)
Trial: 33263237
Drug: Plate fixation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plate fixation and placebo injection at the fracture line
Trial: 35751892
Drug: Liraglutide (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (0.6 mg)
Trial: 33399989
Drug: Liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.8 mg)
Trial: 33819495
Drug: 3-mg granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-mg granisetron
Trial: 33819495
Drug: 1-mg granisetron
RxNorm normalized name: granisetron 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-mg granisetron
Trial: 33616815
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Arm 3)
Trial: 32356023
Drug: Caffeine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3 mg kg‐1)
Trial: 36400089
Drug: Influenza vaccine
RxNorm normalized name: Influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza vaccine (0.5 ml intramuscularly once a year for up to 3 years)
Trial: 32185143
Drug: DNA extraction
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA extraction with specific pre‐treatments
Trial: 35999527
Drug: NEPA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEPA and DEX (12 mg) on day 1, no further DEX (DEX1)
Trial: 35999527
Drug: NEPA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEPA and DEX (12 mg) on day 1, oral DEX (4 mg daily) on days 2-3 (DEX3)
Trial: 35999527
Drug: DEX (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX (4 mg twice daily) on days 2-4 (DEX4; control)
Trial: 33964430
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) 1 g plus 100 mL saline
Trial: 33964430
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (100 mL saline)
Trial: 35450161
Drug: Moderate walking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate walking thrice weekly (MOD × 3/week)
Trial: 35450161
Drug: Moderate walking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate walking once weekly (MOD × 1/week)
Trial: 35450161
Drug: Vigorous walking
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigorous walking once weekly (VIG × 1/week)
Trial: 36030400
Drug: Double-dose quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-dose quadrivalent inactivated vaccine before hospital discharge
Trial: 33848441
Drug: Vibrating Mesh
RxNorm normalized name: MIcroAir Vibrating Mesh Nebulizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibrating Mesh Nebulizer (VMN) with salbutamol (2.5 mg)
Trial: 33848441
Drug: Jet Nebulizer
RxNorm normalized name: Pari LC Jet Nebulizer Plus RE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jet Nebulizer (JN) with salbutamol (2.5 mg)
Trial: 36164681
Drug: Fluoroscopy-guided transforaminal
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroscopy-guided transforaminal epidural steroid injection (TFESI)
Trial: 32273696
Drug: Ginseng capsules
RxNorm normalized name: Nature's Way Asian Ginseng Capsules
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginseng capsules (200 mg, twice per day)
Trial: 37804858
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart
Trial: 32674036
Drug: Patient-centred medication
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-centred medication self-management support programme conducted by trained nurses
Trial: 32116248
Drug: Learning Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Learning Therapy (LT), a combination of cognitive training and stimulation.
Trial: 35630024
Drug: Bevacizumab (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (7.5 mg/kg every three weeks up to 17 cycles) combined with carboplatin (AUC 6) and paclitaxel (175 mg/m2 for the first six cycles)
Trial: 36846742
Drug: Self-guided lifestyle
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-guided lifestyle intervention (ACTIVATE) including 1 virtual group session, digital tools (wireless scale, self-monitoring app), access to self-paced content via a secure website, and 12 weekly texts to reinforce health risk messaging
Trial: 33794181
Drug: Long-acting cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting cabotegravir (400 mg) and rilpivirine (600 mg) administered as two 2 mL intramuscular injections every 4 weeks for at least 96 weeks.
Trial: 33794181
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care regimen (daily oral dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg for 20 weeks followed by continuation).
Trial: 35276572
Drug: Psychotherapy (acceptance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy (acceptance and commitment therapy)
Trial: 32164435
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion
Trial: 34704709
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% plus 50 µg fentanyl (1 mL)
Trial: 36047623
Drug: Telehealth treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telehealth treatment
Trial: 34732236
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) administered to intensive induction therapy on days 1, 4, and 7
Trial: 34732236
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) administered once on day 1 (GO-1)
Trial: 34732236
Drug: Glasdegib as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glasdegib as adjunct to consolidation therapy and as single-agent maintenance therapy for six months
Trial: 34732236
Drug: Placebo as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as adjunct to consolidation therapy and as single-agent maintenance therapy for six months
Trial: 32907619
Drug: Hydroxychloroquine combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine combined with low-dose prednisone and anticoagulation
Trial: 36201773
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (weekly text messages inquiring about infant feeding method)
Trial: 32398443
Drug: Pregabalin 75
RxNorm normalized name: pregabalin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 75 mg/d
Trial: 39378042
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily
Trial: 35388606
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin (0.5 mg/kg once daily for 16 weeks)
Trial: 35388606
Drug: Oral isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isotretinoin (0.5 mg/kg once daily for 16 weeks) + SM peeling (20% salicylic and 10% mandelic acid every 4 weeks for 16 weeks)
Trial: 34062484
Drug: Nintedanib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nintedanib (200 mg b.i.d. p.o. until disease progression)
Trial: 34062484
Drug: Ifosfamide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide (3 g/m2 i.v. days 1–3, every 21 days for ≤6 cycles)
Trial: 36179790
Drug: 120-second MicroPulse
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120-second MicroPulse Transscleral Laser Therapy (Total Energy 93.9J, Fluence 131.0J/cm2)
Trial: 36179790
Drug: 100-second MicroPulse
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100-second MicroPulse Transscleral Laser Therapy (Total Energy 78.25J, Fluence 109.2J/cm2)
Trial: 36179790
Drug: 120-second MicroPulse
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120-second MicroPulse Transscleral Laser Therapy
Trial: 32090434
Drug: Plasminogen activator
RxNorm normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasminogen activator inhibitor-1 (PAI-1) levels at 1st assessment (1992-1993)
Trial: 32090434
Drug: Plasminogen activator
RxNorm normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plasminogen activator inhibitor-1 (PAI-1) levels at 2nd assessment (2005-2006)
Trial: 32870153
Drug: 4-mg perampanel
RxNorm normalized name: perampanel 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mg perampanel fine granules (FG)
Trial: 32870153
Drug: 4-mg perampanel
RxNorm normalized name: perampanel 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mg perampanel tablet
Trial: 35532041
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy
Trial: 37515459
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (control group)
Trial: 35790010
Drug: Low-TBS dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-TBS dosage (1.91–2.07 mg/kg)
Trial: 35790010
Drug: High-TBS dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-TBS dosage (4.27–4.88 mg/kg)
Trial: 34081848
Drug: Olaparib (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib (1 year of oral treatment)
Trial: 34081848
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 year of treatment)
Trial: 37745479
Drug: Low-dose propofol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose propofol
Trial: 35331498
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive use (COC, n=9)
Trial: 35411611
Drug: Lixisenatide 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 5, 10, and 20 μg once daily for 6 weeks
Trial: 36569174
Drug: Standard regulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regulated treatment for chronic non-communicable diseases
Trial: 34116330
Drug: Azithromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (250 mg, BID, three days a week)
Trial: 34116330
Drug: Prednisolone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (5 mg, BID)
Trial: 35090540
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine e-aid Cognitive Behavioral Therapy for Insomnia (TCM-eCBT-I)
Trial: 33990151
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (health education, psychological intervention, and training of the oral muscle group)
Trial: 33111942
Drug: Low-dose NGF
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose NGF (1 µg) injections
Trial: 33111942
Drug: Control injections
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control injections of isotonic saline
Trial: 32757634
Drug: Osmotic Release
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH)